BBK Worldwide Harnesses Apple iPad® to Support Speed-to-Market for Investigational Treatments


Company News Release

BBK Worldwide is introducing a Patient Recruitment Franchise Program. BBK’s flagship product for its new program is the FRANCHISE e-BINDERSM: a communication platform that uses the Apple iPad® to facilitate the myriad processes necessary to effectively recruit and manage patients for global clinical trials.

This new franchise model supports quick, efficient enrollment for multiple studies within the same therapeutic category, as well as multiple protocols for a single compound. “Franchise programs create savings through the economies of scale derived from applying strategies and tactics across multiple studies and countries,” said Joan F. Bachenheimer, BBK Worldwide founding principal and CEO. “Using the model of the Patient Recruitment Franchise Program, sponsors are able to consolidate planning and recruitment strategies for immediate and long-term cost reductions.”

The Apple iPad supports franchise-level initiatives by making it possible to instantly distribute, store, and retrieve information and data with the tap of a finger. “BBK’s application of this new technology skillfully supports clinical research professionals as they work to manage the avalanche of information surrounding clinical trial particulars,” said Matthew Stumm, BBK Worldwide creative director. Consider the following audience-specific applications of the FRANCHISE e-BINDER, powered by BBK partner company TCN e-Systems:

· Investigator meetings made simple
· Top-level data sourced and easily retrieved for clinical operations
· The STUDY MANAGER e-BINDERSM offers one-stop access to critical forms, inclusion/exclusion criteria, patient materials, etc.Can be adapted for any country/language.
· The UPDATE e-BINDERSM for clinical study managers and monitors provides a hand-held portal to site administration resources – including training, study contact listings, sponsor documentation, clinical assessment tools

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.